Alipogene Tiparvovec for the Treatment of LPLD Patients

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped uniQure, has decided not to renew the Marketing Authorization of Glybera in the EU. This decision is not related to any safety, efficacy or quality issue

Conditions

LPL Deficiency

Interventions

DRUG: alipogene tiparvovec
DRUG: Prednisolone
DRUG: Cyclosporins
DRUG: Mycophenolate mofetil

Sponsor

UniQure Biopharma B.V.

Collaborators

[object Object]